{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Eledon Pharmaceuticals, Inc."},"Symbol":{"label":"Symbol","value":"ELDN"},"Address":{"label":"Address","value":"19900 MACARTHUR BOULEVARD,SUITE 550, IRVINE, California, 92612, United States"},"Phone":{"label":"Phone","value":"+1 949 238-8090"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's lead compound in development is AT-1501 which is the next generation anti-CD40L antibody."},"CompanyUrl":{"label":"Company Url","value":"https://www.eledon.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"David-Alexandre C. Gros","title":"Chief Executive Officer & Director"},{"name":"Eliezer Katz","title":"Chief Medical Officer"},{"name":"John Herberger","title":"Vice President-Technical Operations"},{"name":"Marina Escudero","title":"Vice President & Head-Clinical Operations"},{"name":"Steven N. Perrin","title":"President, Chief Scientific Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}